Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • US: HIV Advocacy Group Spars With Express Scripts Over HIV Drug Formulary Changes

    Express Scripts, one of the largest pharmacy benefit managers (PBMs) in the U.S., recently updated its list of preferred medicines to exclude seven common HIV drugs, swapping those drugs for 18 "preferred alternatives."

    8 hours ago | The BodyPro
  • CytoDyn: Uncovering An Opportunity

    CytoDyn is moving their PRO 140 product candidate closer towards an FDA approval in HIV.

    12 June 2019 | Seeking Alpha
  • Global ingredient shortage caused ARV stockouts

    A worldwide shortage of an active pharmaceutical ingredient is the reason behind the anti-retroviral (ARV) medication shortfall across the country, the department of health confirmed. The anti-retroviral drug called Lamivudine is currently in short supply globally and this has affected ARVs that contain this ingredient.

    07 June 2019 | Health-e
  • This drug could end HIV. Why hasn't it? (Podcast)

    Dr. Robert Grant developed a treatment — a daily pill known as pre-exposure prophylaxis, or PrEP — that could stop the AIDS crisis. We look at why that hasn’t happened.

    06 June 2019 | New York Times
  • WHO agrees watered-down resolution on transparency in drug costs

    Countries at the World Health Organization agreed on Tuesday to push for clearer drug pricing, after watering down a draft resolution that would have also required pharmaceutical firms to disclose the cost of making medicines.

    02 June 2019 | Reuters
  • World Health Assembly Approves Milestone Resolution On Price Transparency

    The World Health Assembly today approved a milestone resolution to support greater public disclosure of prices for medicines and other health products – capping a nail-biting series of negotiations that continued until the very moment the measure came to the floor. In a highly unusual move, Germany, the United Kingdom and Hungary “disassociated” themselves from the measure, “Improving the transparency of markets for medicines, vaccines and other health products,” complaining that its far-reaching implications were not fully appreciated, and that the four-month review period since the draft resolution’s submission by lead sponsor Italy had been insufficient.

    02 June 2019 | Health Policy Watch
  • Is Off-Label HIV Prevention Better Than None?

    Rather than prescribe F/TDF as PrEP, Michael Saag, MD said, prescribers should sidestep the brand-name product and instead give their PrEP-eligible patients a generic HIV drug combination that uses lamivudine (3TC) with TDF.

    31 May 2019 | MedPage Today (requires free registration)
  • The truth is you can afford the medication that prevents HIV. Here’s how.

    It’s not the cost of PrEP that keeps more patients from accessing it; it’s the lack of awareness and the daunting nature of our complicated healthcare system.

    24 May 2019 | LGBTQ Nation
  • A Review of the Congressional Hearing on HIV Drug Pricing

    In an effort to best encapsulate the remarks of many of the members of the House and the powerful testimony of the HIV advocates present at the recent Congressional hearing on drug pricing around Gilead Sciences’ HIV prevention drug Truvada, we thought it was best to provide you with their own words.

    23 May 2019 | POZ
  • Analysis reveals extent of drug industry funding of UK patient organisations

    The researchers call for greater transparency to ensure that industry funding is not unduly influenced by commercial objectives.

    23 May 2019 | The BMJ press release
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.